Lawrence Phillips, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1073532354
Payments from drug & device makers
What this record shows
Janssen Research & Development, LLC accounts for 83.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $2,197 and has fallen 91.0% since, to $197 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in GA, where the typical reported total is $2,873.
Across 16 payments — averaging $165.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2K
- BETA Bionics, Inc.$197
- Sanofi-aventis U.S. LLC$131
- Janssen Scientific Affairs, LLC$123
Across 153 payments — averaging $5990.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$488K
- Pfizer$385K
- AbbVie$32K
- GSK$10K
- Abbott$2K
What the payments were for
- Travel & lodging$1,57760%
- Food & beverage$1,07040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 13 | $2,197 |
| BETA Bionics, Inc. | 1 | $197 |
| Sanofi-aventis U.S. LLC | 1 | $131 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$590
- TZIELD$131
- INVOKANA$123
How this compares
$2,647 in reported general payments places this provider in the 45th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenotropinSomatropin | 17 | $108,768 |
| MounjaroTirzepatide | 62 | $77,235 |
| TymlosAbaloparatide | 26 | $66,894 |
| OzempicSemaglutide | 47 | $60,646 |
| JardianceEmpagliflozin | 46 | $53,534 |
| JanuviaSitagliptin Phosphate | 15 | $20,945 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $19,965 |
| Potassium Chloride | 24 | $15,423 |
| DuaveeEstrogens,conj/Bazedoxifene | 15 | $5,103 |
| SynthroidLevothyroxine Sodium | 16 | $1,809 |
| Hydrocortisone | 45 | $1,667 |
| Desmopressin Acetate | 17 | $1,614 |
| Levothyroxine Sodium | 127 | $1,279 |
| Eplerenone | 12 | $743 |
| Verapamil ErVerapamil Hcl | 19 | $525 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Jonathan OwnbyAtlanta$291K
- Gulliermo UmpierrezAtlanta$63K
- Francisco PasquelAtlanta$40K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- Kate WheelerAtlanta$17K
- John ZoraAtlanta$16K
- Ernest BeasleyAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.